Covance
Home About Covance Investor Relations News Careers Contact Us
Home > Financial Info > Press Releases
 Advanced Search
Take me to...
Find a service
Drug Development Services
Nonclinical
Clinical
Commercialization
Industries We Serve
Biotech
Environmental
Food & Dietary Supplements
Pharma
Research
Vaccines
Antibody Products Store
Volunteer for a Study
Investigators
Information Library
Animal Welfare
COVANCE REPORTS RECORD 2Q98 FINANCIAL RESULTS; REVENUES UP 25.2%, NET INCOME UP 22.3%
Covance Continues To Lead Advancements In Drug Development

Second Quarter Highlights:
  • Covance continues to deliver solid, balanced, diversified growth as it has in all quarters as an independent public company

  • Second quarter revenues up 25.2%

  • Second quarter net income up 22.3%

  • Covance Board of Directors expanded by the election of Kathleen G. Murray, Chief Operating Officer of Northwestern Memorial Corporation, a premier medical institution based in Chicago

  • Covance information technology systems recognized for innovation and excellence by The Smithsonian Institute

  • Initiated facility expansion for new 200,000 square foot clinical packaging site in Allentown, Pennsylvania

  • Covance awarded first ever Chinese Government sponsored development work for two Traditional Chinese Medicines (botanically derived)
Princeton, NJ, July 21, 1998 — Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development service companies, today reported strong financial results for its second quarter ended June 30, 1998.

Net revenues for the second quarter of 1998 were $182.1 million, up 25.2% compared to $145.4 million for the second quarter of 1997. Year-to- date, net revenues were $350.6 million, up 24.7% compared to $281.1 million for the same period in 1997.

Operating income for the second quarter of 1998 was $24.3 million, up 20.2% compared to $20.2 million for the second quarter of 1997. Year-to-date, operating income was $44.6 million, up 19.4% compared to $37.4 million for the first six months of 1997.

Net income for the second quarter of 1998 was $12.9 million or $0.22/share, up 22.3% compared to $10.5 million or $0.18/share for the second quarter of 1997. Year-to-date, net income was $23.3 million or $0.40/share, up 21.8% compared to $19.1 million or $0.33/share for the first half of 1997.

"Covance continues to leverage its global reach and comprehensive drug development expertise to build on its already strong presence in the fast- growing drug development services marketplace," noted Chris Kuebler, Chairman and Chief Executive Officer. "Our consistently strong revenue and earnings growth are a reflection of our ability to repeatedly deliver high value-added services to our clients."


Strategic Board addition; Smithsonian recognition; Strong industry fundamentals

Kathleen G. Murray, Chief Operating Officer of Northwestern Memorial Corporation, a premier medical institution based in Chicago, recently was elected to Covance's Board of Directors. Ms. Murray's expertise in running a world class medical institution and her extensive knowledge of patient issues and standards of medical care will strengthen Covance's ability to further mrefine and enhance the drug development process for its clients.

Covance's continued investment in cutting edge technology was rewarded with the recognition of two of its proprietary information systems — Drug Management and Data Review — by The Smithsonian Institute. These information systems were included in the Smithsonian Institute's permanent research collection on Information Technologies and recognized for their innovation and excellence. These systems have a proven ability to optimize the management of clinical drug supplies, to enhance the quality of clinical data and ultimately, accelerate drug development.

The pharmaceutical industry is perhaps at its most productive level in history, testing and introducing novel, life-saving therapies at an unprecedented pace. "These are exciting times for the pharmaceutical industry and for Covance," said Chris Kuebler. "Our clients have outstanding pipelines and we are excited about our prospects. Covance is uniquely positioned to capitalize on these strong market dynamics."

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development service companies, with 1997 revenues of approximately $590 million, operations currently in 17 countries, and 6,600 employees worldwide. Covance's purpose is to lead advancements in drug development through science, service and shaping solutions. Covance strives to achieve this goal by combining superior development expertise and global presence to provide broad based drug development capabilities including preclinical, biomanufacturing, central laboratory, clinical packaging, clinical, periapproval and health economics services to the world's pharmaceutical, biotechnology and medical device companies.


Statements contained in this press release which are not historical facts may be considered forward-looking statements as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on Covance's expectations and are subject to a number of risks and uncertainties, certain of which are beyond Covance's control. Actual results could differ materially from these forward-looking statements as a result of a variety of factors including the risk factors described in Covance's filings with the Securities and Exchange Commission such as (i) Covance has only recently been operating as a separate independent company, (ii) changes in regulations governing the drug development process, and (iii) the fixed price nature of contracts or the loss of large contracts. In light of these risks and uncertainties, there can be no assurance that any forward-looking information contained in this press release will in fact transpire.
SEC Filings
Annual Reports
Quarterly Reports
Press Releases
                                 COVANCE INC.
                              INCOME STATEMENTS
          FOR THE THREE AND SIX  MONTHS ENDED JUNE 30, 1998 AND 1997
                (Dollars in thousands, except per share data)
                                 (UNAUDITED)

                              Three Months Ended          Six Months Ended
                                    June 30                   June 30
                               1998         1997         1998          1997

    Net Revenues          $182,089      $145,392     $350,598      $281,115

    Costs and expenses:
    Cost of revenue        119,338        95,154      232,066       185,979
    Selling, general &
     administrative expense 29,426        22,595       56,339        43,246
    Depreciation and
     amortization            9,023         7,421       17,577        14,529
    Total                  157,787       125,170      305,982       243,754


    Income from operations  24,302        20,222       44,616        37,361

    Other expense, net:
    Interest expense, net    1,808         2,173        3,503         4,188
    Other expense (income)      74         (525)          187          (51)
    Other expense, net       1,882         1,648        3,690         4,137

    Income before taxes and
     equity investee results22,420        18,574       40,926        33,224

    Taxes on income          9,388         7,940       17,248        14,093

    Equity investee loss (gain)164           115          358          (15)

    Net income             $12,868       $10,519      $23,320       $19,146

    Basic earnings per share $0.22         $0.18        $0.40         $0.34

    Weighted average shares
     outstanding - basic57,953,563    57,125,803   57,864,438    57,094,723

    Diluted earnings per
     share                   $0.22         $0.18        $0.40         $0.33

    Weighted average
     shares outstanding -
     diluted            58,457,280    57,202,694   58,290,610    57,229,411


                                 COVANCE INC.
                         CONDENSED BALANCE SHEET DATA
                     JUNE 30, 1998 AND DECEMBER 31, 1997
                            (Dollars in thousands)
                            
                                     June 30,          December 31,
                                      1998                1997
                                   (UNAUDITED)

    CONDENSED BALANCE SHEET DATA

    Cash and cash equivalents     $11,231                 $28,027
    Accounts and unbilled
     receivables                $ 177,609               $ 145,769
    Total Current Assets        $ 251,898               $ 230,478
    Total Assets                $ 509,295               $ 484,014

    Total Current Liabilities   $ 162,740               $ 170,990
    Long-term debt              $ 136,910               $ 132,423
    Total Liabilities           $ 324,004               $ 326,957
    Total Stockholders' Equity  $ 185,291               $ 157,057


                                 COVANCE INC.
                           CONDENSED CASH FLOW DATA
               FOR THE SIX MONTHS ENDED JUNE 30, 1998 AND 1997
                            (Dollars in thousands)
                                 (UNAUDITED)

                                        Six Months Ended June 30
                                      1998                   1997

    CONDENSED CASH FLOW DATA


    Cash flows from net earnings
     adjusted for non-cash
     activity                    $ 45,614                $ 35,432
    Changes in operating assets
     and liabilities             (46,534)                 (6,614)
    Net cash (used in) provided
     by operating activities        (920)                  28,818

    Capital expenditures         (23,523)                (22,354)
    Other, net                         54                      85

    Net proceeds from
     (repayment of) debt            5,000                 (5,950)

    Cash provided by stock issued
     under employee benefit plans   2,593                   1,082
    Net change in cash and
     cash equivalents            (16,796)                   1,681
    Cash and cash equivalents,
     beginning of period           28,027                  25,416
    Cash and cash equivalents,
     end of period               $ 11,231                $ 27,097

SOURCE  Covance Inc.